MBRI-001 is a deuterium-substituted plinabulin derivative and a potent anti-cancer agent with better pharmacokinetic characteristics tand lower toxicity.
Anpirtoline free base is a highly potent 5-HT1B receptor agonist. Anpirtoline has been shown to decreases central serotonin synthesis and attenuate aggressive behavior in vivo. Anpirtoline also acts as an antagonist at 5-HT3 receptors and can bypass the blood-brain barrier.